Ann Hematol (2017) 96:1591–1593 DOI 10.1007/s00277-017-3064-0 LETTER TO THE EDITOR Advanced chronic myelomonocytic leukemia in elderly and frail patients managed by azacitidine in the field of clinical practice 1 1 1 1 Pasquale Niscola & Andrea Tendas & Elisabetta Abruzzese & Tommaso Caravita & 1 1 1 1 Luca Cupelli & Marco Giovannini & Laura Scaramucci & Agostina Siniscalchi & 1 1 Monika Malgorzata Trawinska & Paolo de Fabritiis Received: 3 June 2017 /Accepted: 4 July 2017 /Published online: 12 July 2017 Springer-Verlag GmbH Germany 2017 Dear Editor, for the role of azacitidine in the CMML management, Chronic myelomonocytic leukemia (CMML) is an despite an overall response rate (ORR) and median aging-related clonal hematopoietic stem cell disorder, overall survival (OS) ranging from 39 to 60% and from classified as myelodysplastic/myeloproliferative disor- 12 to 37 months respectively reported by some studies ders . Indeed, its disease phenotype usually combines [4–7] outside clinical trials, a matched-pair analyses of myelodysplastic (MD) and myeloproliferative (MP) fea- real-life CMML patients showed that this epigenetic tures. Therefore, other than a persistent peripheral agent do not modify the natural course of the disease monocytosis representing the hematological disease hall- . Therefore, with the exception of patients
Annals of Hematology – Springer Journals
Published: Jul 12, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera